Insider Trading Alert - SBCF, VVUS And ACN Traded By Insiders

Yesterday, April 11, 2016, 34 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $60.52 to $14,857,800.00.

Highlighted Stocks Traded by Insiders:

Seacoast Banking (SBCF) - FREE Research Report

Bohner Stephen E, who is Director at Seacoast Banking, sold 4 shares at $15.13 on April 11, 2016. Following this transaction, the Director owned 1,701 shares meaning that the stake was reduced by 0.23% with the 4-share transaction.

The shares most recently traded at $15.89, up $0.76, or 4.78% since the insider transaction. Historical insider transactions for Seacoast Banking go as follows:

  • 4-Week # shares bought: 128
  • 4-Week # shares sold: 400
  • 12-Week # shares bought: 128
  • 12-Week # shares sold: 32
  • 24-Week # shares bought: 3,328
  • 24-Week # shares sold: 32

The average volume for Seacoast Banking has been 83,600 shares per day over the past 30 days. Seacoast Banking has a market cap of $546.1 million and is part of the financial sector and banking industry. Shares are up 5.27% year-to-date as of the close of trading on Wednesday.

Seacoast Banking Corporation of Florida operates as the bank holding company for Seacoast National Bank that provides community banking services to the commercial, small business, and retail customers in Florida. The company has a P/E ratio of 23.9. Currently, there are 2 analysts who rate Seacoast Banking a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SBCF - FREE

TheStreet Quant Ratings rates Seacoast Banking as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Seacoast Banking Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vivus (VVUS) - FREE Research Report

Varghese Santosh T, who is Chief Medical Officer at Vivus, sold 1,882 shares at $1.07 on April 11, 2016. Following this transaction, the Chief Medical Officer owned 101,891 shares meaning that the stake was reduced by 1.81% with the 1,882-share transaction.

The shares most recently traded at $1.75, up $0.68, or 38.74% since the insider transaction. Historical insider transactions for Vivus go as follows:

  • 4-Week # shares bought: 3,080
  • 4-Week # shares sold: 24,995
  • 12-Week # shares bought: 3,080
  • 12-Week # shares sold: 24,995
  • 24-Week # shares bought: 3,080
  • 24-Week # shares sold: 24,995

The average volume for Vivus has been 1.1 million shares per day over the past 30 days. Vivus has a market cap of $170.7 million and is part of the health care sector and drugs industry. Shares are up 74.51% year-to-date as of the close of trading on Wednesday.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. Currently, there is 1 analyst who rates Vivus a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VVUS - FREE

TheStreet Quant Ratings rates Vivus as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Vivus Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Accenture (ACN) - FREE Research Report

Magner Marjorie, who is Director at Accenture, sold 3,000 shares at $112.49 on April 11, 2016. Following this transaction, the Director owned 25,952 shares meaning that the stake was reduced by 10.36% with the 3,000-share transaction.

The shares most recently traded at $112.10, down $0.39, or 0.35% since the insider transaction. Historical insider transactions for Accenture go as follows:

  • 4-Week # shares sold: 99,329
  • 12-Week # shares sold: 102,314
  • 24-Week # shares sold: 241,391

The average volume for Accenture has been 3.4 million shares per day over the past 30 days. Accenture has a market cap of $73.8 billion and is part of the technology sector and computer software & services industry. Shares are up 9.73% year-to-date as of the close of trading on Wednesday.

Accenture plc provides management consulting, technology, and outsourcing services worldwide. The stock currently has a dividend yield of 1.93%. The company has a P/E ratio of 19.9. Currently, there are 10 analysts who rate Accenture a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACN - FREE

TheStreet Quant Ratings rates Accenture as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Accenture Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.